CRIS Current Research Information System

GATTI, MILO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.765
EU - Europa 4.484
NA - Nord America 3.310
SA - Sud America 391
AF - Africa 193
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 3
AN - Antartide 1
Totale 14.173
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.231
IT - Italia 2.545
SG - Singapore 1.972
CN - Cina 1.949
VN - Vietnam 579
NL - Olanda 414
KR - Corea 370
DE - Germania 363
HK - Hong Kong 363
BR - Brasile 293
IN - India 262
SE - Svezia 241
GB - Regno Unito 200
RU - Federazione Russa 145
IE - Irlanda 108
FI - Finlandia 107
CI - Costa d'Avorio 103
JP - Giappone 81
FR - Francia 75
ID - Indonesia 73
BG - Bulgaria 61
CH - Svizzera 52
AR - Argentina 49
CA - Canada 48
AT - Austria 41
ES - Italia 36
TG - Togo 32
PL - Polonia 27
MX - Messico 25
AU - Australia 23
ZA - Sudafrica 16
PE - Perù 14
TR - Turchia 14
NG - Nigeria 13
JO - Giordania 12
BD - Bangladesh 11
UA - Ucraina 11
EC - Ecuador 10
BE - Belgio 9
HR - Croazia 9
IL - Israele 9
PY - Paraguay 8
SA - Arabia Saudita 8
CL - Cile 7
SC - Seychelles 7
TW - Taiwan 7
CO - Colombia 6
IQ - Iraq 6
LT - Lituania 6
PH - Filippine 6
AE - Emirati Arabi Uniti 5
KE - Kenya 5
MY - Malesia 5
PK - Pakistan 5
UZ - Uzbekistan 5
CY - Cipro 4
DK - Danimarca 4
IR - Iran 4
MA - Marocco 4
PT - Portogallo 4
RO - Romania 4
TH - Thailandia 4
CZ - Repubblica Ceca 3
EG - Egitto 3
GR - Grecia 3
NP - Nepal 3
NZ - Nuova Zelanda 3
RS - Serbia 3
SM - San Marino 3
TN - Tunisia 3
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BO - Bolivia 2
CV - Capo Verde 2
EU - Europa 2
LV - Lettonia 2
PA - Panama 2
AL - Albania 1
AO - Angola 1
AQ - Antartide 1
AZ - Azerbaigian 1
BW - Botswana 1
CR - Costa Rica 1
GP - Guadalupe 1
JM - Giamaica 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LB - Libano 1
LU - Lussemburgo 1
MD - Moldavia 1
ME - Montenegro 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
PR - Porto Rico 1
PS - Palestinian Territory 1
RE - Reunion 1
SK - Slovacchia (Repubblica Slovacca) 1
UG - Uganda 1
UY - Uruguay 1
VE - Venezuela 1
Totale 14.171
Salva come PNG Salva come JPEG
Città #
Singapore 1.316
Hefei 864
Ashburn 507
Seoul 365
Bologna 361
Hong Kong 358
Santa Clara 304
Milan 274
Chandler 256
Rome 195
Beijing 186
Ho Chi Minh City 150
Boardman 144
Dallas 121
Princeton 118
Dublin 107
Hanoi 104
Abidjan 103
Southend 103
Fairfield 98
Los Angeles 91
Dong Ket 83
Bengaluru 81
Tokyo 71
New York 69
Sofia 61
Redmond 60
Turin 59
Florence 57
Redondo Beach 57
Jakarta 55
Naples 52
Lappeenranta 49
Buffalo 48
Seattle 45
Nuremberg 43
Castel Maggiore 41
Helsinki 40
Houston 40
Genoa 39
Munich 34
São Paulo 34
Bern 33
Lomé 32
Chicago 30
Verona 30
Woodbridge 29
Berlin 27
Cambridge 27
Des Moines 27
Shanghai 27
Bari 25
Modena 24
Wilmington 24
Falkenstein 23
Mumbai 23
Tongling 23
London 22
Vienna 22
Toronto 21
Vicenza 21
Boydton 20
Frankfurt am Main 20
San Diego 20
Tappahannock 20
Bremen 19
Guangzhou 19
Turku 18
Padua 17
Amsterdam 15
The Dalles 15
Ann Arbor 14
Catania 14
Chengdu 14
Lecce 14
Palermo 14
Reggio Emilia 14
Tianjin 14
Trieste 14
Warsaw 14
Cesena 13
Da Nang 13
Quận Bình Thạnh 13
Amman 12
Boston 12
Bühl 12
Casalecchio di Reno 12
Copertino 12
Denver 12
Forlì 12
Haiphong 12
Zhengzhou 12
Mexico City 11
Venice 11
Brescia 10
Brisbane 10
Buenos Aires 10
Cagliari 10
Hangzhou 10
Lima 10
Totale 8.271
Salva come PNG Salva come JPEG
Nome #
Targeted Therapy of Severe Infections Caused by Staphylococcus aureus in Critically Ill Adult Patients: A Multidisciplinary Proposal of Therapeutic Algorithms Based on Real-World Evidence 291
An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of infection-related ventilator associated complications (IVACs) caused by Enterobacterales in critically ill adult patients 287
Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system 273
Impact of a newly established expert clinical pharmacological advice program based on TDM results in tailoring antimicrobial therapies hospital-wide in a tertiary university hospital: findings after the first-year of implementation 237
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam in a case series of critically ill renal patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-associated pneumonia 210
Artificial Intelligence model to predict resistances in Gram-negative bloodstream infections 204
Pharmacokinetic and pharmacodynamic considerations for optimizing antimicrobial therapy used to treat bone and joint infections: an evidence-based algorithmic approach 184
A descriptive case series of the relationship between maintenance of conservative PK/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infections 172
Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics 172
Advances in the therapy of bacterial bloodstream infections 171
Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis 168
Management of intra-abdominal infections: recommendations by the Italian council for the optimization of antimicrobial use 162
Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams 161
Assessment of a pk/pd target of continuous infusion beta-lactams useful for preventing microbiological failure and/or resistance development in critically ill patients affected by documented gram-negative infections 161
Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future 159
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam for treating DTR gram-negative infections in a case series of critically ill patients undergoing continuous veno-venous haemodiafiltration (CVVHDF) 155
Therapeutic drug monitoring of ceftazidime/avibactam: why one leg is not enough to run 152
Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP 149
Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing 149
A Sensitive Liquid Chromatography–Tandem Mass Spectrometry Method for Measuring Fosfomycin Concentrations in Human Prostatic Tissue 147
Critical reappraisal of current issues for improving the proper clinical use of the incoming beta-lactam/beta-lactamase inhibitor combinations of tomorrow 145
Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant Pseudomonas aeruginosa Bloodstream Infections and/or Hospital-Acquired Pneumonia 145
A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE) bloodstream infections 144
Tolerability of pulsed high-dose L-AmB as pre-emptive therapy in patients at high risk for intra-abdominal candidiasis: A phase 2 study (LAMBDA study) 141
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance 141
Breakthrough invasive fungal infection after liver transplantation in patients on targeted antifungal prophylaxis: A prospective multicentre study 141
Pharmacokinetics/pharmacodynamics of cefiderocol administered by continuous infusion in a case series of critically ill patients with carbapenem-resistant Acinetobacter baumannii infections undergoing continuous venovenous haemodiafiltration (CVVHDF) 139
Impact of a multidisciplinary management team on clinical outcome in ICU patients affected by Gram-negative bloodstream infections: a pre-post quasi-experimental study 137
Efficacy of a Novel Prophylactic Scheme of Fosfomycin Trometamol in Patients Undergoing Endoscopic Surgery for Benign Prostatic Hyperplasia: Findings from a Prospective Monocentric Single-Arm Study 136
Impact of Inflammation on Voriconazole Exposure in Critically ill Patients Affected by Probable COVID-19-Associated Pulmonary Aspergillosis 135
Impact of attaining an aggressive PK/PD target with continuous infusion beta-lactams on the clinical efficacy of targeted therapy of early post-transplant Gram-negative infections in critically ill OLT recipients. An interim analysis of a 3-year prospective, observational, study 133
A pre-post quasi-experimental study of antimicrobial stewardship exploring the impact of a multidisciplinary approach aimed at attaining an aggressive joint pharmacokinetic/pharmacodynamic target with ceftazidime/avibactam on treatment outcome of KPC-producing Klebsiella pneumoniae infections and on ceftazidime/avibactam resistance development 129
A descriptive case series of PK/PD target attainment and microbiological outcome in critically ill patients with documented severe XDR Acinetobacter baumannii BSI and/or VAP treated with cefiderocol 128
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems 128
Implementation and validation of a Bayesian method for accurately forecasting duration of optimal pharmacodynamic target attainment with dalbavancin during long-term use for treating subacute and/or chronic staphylococcal infections 127
Relationship Between Real-time TDM-guided Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam Monotherapy and Microbiologic Outcome in the Treatment of Critically Ill Children With Severe Documented Gram-negative Infections 126
Adaptive trials of new antimicrobials for infections with carbapenem-resistant, Gram-negative bacteria 126
The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia 125
Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration 124
A Proof of Concept of the Role of TDM-Based Clinical Pharmacological Advices in Optimizing Antimicrobial Therapy on Real-Time in Different Paediatric Settings 124
Real-Time TDM-Guided Optimal Joint PK/PD Target Attainment of Continuous Infusion Piperacillin–Tazobactam Monotherapy Is an Effective Carbapenem-Sparing Strategy for Treating Non-Severe ESBL-Producing Enterobacterales Secondary Bloodstream Infections: Findings from a Prospective Pilot Study 123
Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections 123
Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: Insight from a pharmacovigilance study 122
Could an optimized joint pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections? 121
Assessing the association between fluoroquinolones and emerging adverse drug reactions raised by regulatory agencies: An umbrella review 120
Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase 120
An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically Ill Adult Patients 120
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis 120
Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem 119
Does therapeutic drug monitoring (TDM) of trough concentrations suffice for optimizing preemptive therapy with ganciclovir of cytomegalovirus infections in non-renal solid organ transplant recipients? 119
Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews 119
Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors 117
The impact of preservation fluid culture on graft site arteritis: a systematic review and metanalysis 116
Highly adsorptive removal of cefiderocol during continuous venovenous hemodiafiltration equipped with oXiris filter in an orthotopic liver transplant recipient having septic shock caused by VIM-producing Klebsiella pneumoniae 116
Fast and Sensitive Analysis of Cefiderocol in Human Plasma Microsamples by Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry for Therapeutic Drug Monitoring 114
Clinical outcome in solid organ transplant recipients affected by COVID-19 compared to general population: a systematic review and meta-analysis 114
Fast and Simple Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Dalbavancin in Long-Term Treatment of Subacute and/or Chronic Infections 112
The Cytokine Release Syndrome and/or the Proinflammatory Cytokines as Underlying Mechanisms of Downregulation of Drug Metabolism and Drug Transport: A Systematic Review of the Clinical Pharmacokinetics of Victim Drugs of this Drug-Disease Interaction Under Different Clinical Conditions 111
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis 110
Assessment of adverse reactions to α-lipoic acid containing dietary supplements through spontaneous reporting systems 109
The expert clinical pharmacological advice program for tailoring on real-time antimicrobial therapies with emerging TDM candidates in special populations: how the ugly duckling turned into a swan 108
Population Pharmacokinetic and Pharmacodynamic Analysis of Dalbavancin for Long-Term Treatment of Subacute and/or Chronic Infectious Diseases: The Major Role of Therapeutic Drug Monitoring 107
Clinical efficacy of cefiderocol-based regimens in patients affected by carbapenem-resistant Acinetobacter baumannii infections: a systematic review with meta-analysis 106
Quantification of 1,3-β-d-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study 105
An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of bsis, cutis, and ciais caused by enterobacterales in critically ill adult patients 104
Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System 101
Real-Time Optimization of Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Gram Negatives with Ceftazidime–Avibactam-Based Regimens: A Report of Two Cases 101
Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization 100
Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like Klebsiella pneumoniae Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring 100
Novel CMY-186 variant conferring cross-resistance to cefiderocol and ceftazidime/avibactam in Klebsiella pneumoniae from a critically ill patient during cefiderocol and ceftazidime/avibactam treatment 98
Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19 98
The European List of Key Medicines for Medical Education: A Modified Delphi Study 97
Reply-Letter to the editor - The valuable support of spontaneous reporting systems in exploring safety profile of dietary supplements 97
Fast and Sensitive Method for Simultaneous Quantification of Meropenem and Vaborbactam in Human Plasma Microsamples by Liquid Chromatography-Tandem Mass Spectrometry for Therapeutic Drug Monitoring 97
An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patients 97
Clinical efficacy of renal dosing adjustments of ceftazidime‐avibactam in patients affected by carbapenem‐resistant Gram‐negative infections: a systematic review and meta‐analysis of observational studies 96
Usefulness of a hub and spoke TDM-guided expert clinical pharmacological advice program of dalbavancin for optimizing very long-term curative or suppressive treatment of chronic staphylococcal infections 95
Piperacillin-tazobactam vs. carbapenems for treating hospitalized patients with ESBL-producing Enterobacterales bloodstream infections: a systematic review and meta-analysis 95
Janus kinase inhibitors and coronavirus disease (Covid)‐19: Rationale, clinical evidence and safety issues 95
Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections 94
Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing Enterobacterales Bloodstream Infections and/or Ventilator-Associated Pneumonia? 92
Suboptimal drug exposure leads selection of different subpopulations of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae in a critically ill patient 90
Drug Interactions with Contraceptives 89
A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion meropenem/vaborbactam in the treatment of critically ill patients with documented KPC-producing Klebsiella pneumoniae ventilator-associated pneumonia 88
Pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam in peritoneal fluid in an orthotopic liver transplant recipient affected by bacteraemic complicated intra-abdominal infection: due to OXA-181-producing Klebsiella pneumoniae 86
Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis 86
Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept 86
Quality of care indicators in the MAnageMent of BlOOdstream infections caused by Enterobacteriaceae (MAMBOO-E study): state of the art and research agenda 86
Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis 86
Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant Staphylococcus aureus: A Retrospective Single-Centre Experience 84
Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections 83
Feasibility of 24 h continuous-infusion cefiderocol administered by elastomeric pump in attaining an aggressive PK/PD target in the treatment of NDM-producing Klebsiella pneumoniae otomastoiditis 83
Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections 83
Should the Clinical Pharmacologist Play a Role in the Multidisciplinary Team Managing Severe Necrotizing Soft-Tissue Infections? 78
Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal 78
Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients 78
Impact on clinical outcome of follow-up blood cultures and risk factors for persistent bacteraemia in patients with gram-negative bloodstream infections: a systematic review with meta-analysis 76
Evidence and current use of levosimendan in the treatment of heart failure: Filling the gap 76
A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: A strategy useful for raising the bar? 75
A Proof of Concept of the Usefulness of a TDM-Guided Strategy for Optimizing Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Ampicillin-Based Regimens in a Case Series of Patients with Enterococcal Bloodstream Infections and/or Endocarditis 75
Totale 12.432
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.808
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.808
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021309 0 0 0 0 0 5 7 46 46 14 42 149
2021/20221.092 57 1 23 47 87 65 120 127 57 96 230 182
2022/20231.455 97 105 75 181 144 106 95 126 243 84 84 115
2023/20241.469 95 108 99 144 129 160 140 144 100 123 113 114
2024/20254.778 182 455 404 380 548 263 501 238 173 446 435 753
2025/20265.397 968 1.246 1.041 915 854 373 0 0 0 0 0 0
Totale 14.609